Skip to main content

Table 1 Comparison of basic characteristics between the polymerase chain reaction-negative conversion group and non-negative conversion group within 28 days (N = 136)

From: Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study

Variables, number (%)

Negative conversion

(N = 53)

Non-negative conversion

(N = 83)

P value

Age, year (mean ± standard deviation)

43.7 ± 17.4

40.5 ± 18.7

0.324

Male gender

28 (52.8)

38 (45.8)

0.423

Epidemiological linkage

  

0.094

 Imported cases

8 (15.1)

21 (25.3)

 

 Household contact

10 (18.9)

22 (26.5)

 

 Non-familial contact

15 (28.3)

20 (24.1)

 

 Cluster outbreak

12 (22.6)

17 (20.5)

 

 Unknown

8 (15.1)

3 (3.6)

 

Co-morbidities

   

 Cardio-pulmonary diseases

9 (17.0)

21 (25.3)

0.254

 Endocrine diseases

5 (9.4)

10 (12.0)

0.635

 Neurological diseases

8 (15.1)

3 (3.6)

0.023

 Other diseases

9 (17.0)

15 (18.1)

0.871

Delayed admission ≥ 3 days

33 (62.3)

49 (59.0)

0.708

Initial symptom

   

 Asymptomatic

4 (7.5)

9 (10.8)

0.524

 General (fever, chill, and myalgia)

33 (62.3)

53 (63.9)

0.851

 Upper respiratory (sore throat, rhinorrhea, and nasal congestion)

15 (28.3)

23 (27.7)

 

 Lower respiratory (cough, sputum, dyspnea, and chest discomfort)

6 (11.3)

36 (43.4)

 < 0.001

 Others

5 (9.4)

4 (4.8)

0.311

Pneumonia on initial chest computed tomography

41 (77.4)

44 (53.0)

0.004